Zhong Guo Zheng Quan Bao·2025-08-27 21:47Core Viewpoint - Kunming Pharmaceutical Group aims to become a leader in the silver-haired health industry, marking a new entrepreneurial journey after being acquired by China Resources Sanjiu [1][2]. Group 1: Integration and Transformation - Following the acquisition, Kunming Pharmaceutical Group is undergoing a systematic restructuring, focusing on value, business, organization, and spirit over a three-year integration period [2]. - The company is transitioning its operational model from "experience-driven" to "data-driven" by leveraging digital tools developed with the support of China Resources Sanjiu [2][3]. - A significant channel reform is underway to consolidate its previously fragmented sales network, establishing a more centralized channel structure [3]. Group 2: Focus on Silver-Haired Health - The new management has prioritized focusing resources on the silver-haired health sector, moving away from previous scattered investments [4]. - The company has a strong foundation in natural medicine research, particularly in chronic disease management and elderly health [5]. - Kunming Pharmaceutical Group is implementing a dual-platform strategy focusing on chronic disease management and premium traditional Chinese medicine [5]. Group 3: Innovative Business Model - The company is developing a three-in-one model that combines pharmaceuticals, medical services, and emotional value, aiming to create a comprehensive health management ecosystem [6]. - Plans include the development of intelligent companionship devices that integrate medical data and AI to support elderly care [6]. Group 4: International Expansion - Kunming Pharmaceutical Group is actively pursuing international markets, particularly in traditional Chinese medicine, with a focus on plant-based medicines like Artemisinin and Sanqi [7]. - The company has submitted 90 overseas registration applications and has successfully registered 7 products, with its blood stasis remedy approved in 15 countries [7]. - The company aims to leverage its global network and expertise in Artemisinin to become a comprehensive international healthcare service provider [8].